Literature DB >> 27466535

Risk Factors of Lymph Nodes Metastases by Endometrial Cancer: A Retrospective One-center Study.

Mustafa Zelal Muallem1, Jalid Sehouli2, Jumana Almuheimid2, Rolf Richter2, Ralf Joukhadar3, Helmut Plett2.   

Abstract

BACKGROUND/AIM: We aimed to identify the surgical-pathological risk factors separately for pelvic and para-aortic lymph nodes (LN) metastases in endometrial cancer (EC). PATIENTS AND METHODS: The study cohort consisted of 179 patients with first diagnosis of EC, who were operated in our Institution between 2007 and 2014.
RESULTS: Pelvic and para-aortic LN dissection was performed in 115 patients (64.2%). The positive pelvic and para-aortic LN were diagnosed in 11.3% and 16.1% of cases, respectively. Patients with bad differentiated tumors (G3) showed about 5-times more risk to have affected LN. Deep infiltration of myometrium elevated the risk of pelvic LN infiltration 5 times and of para-aortic LN infiltration 14 times. G3, myometrial infiltration >50% and type II endometrial cancer correlated with a worse progression free survival (PFS) and overall survival (OS).
CONCLUSION: Tumor grade and deep myometrial invasion were the only significant predictors of pelvic and para-aortic lymph node metastases. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Risk factor; endometrial cancer; lymph node metastases

Mesh:

Year:  2016        PMID: 27466535

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Survival outcomes of women with grade 3 endometrioid endometrial cancer: the impact of adjuvant treatment strategies.

Authors:  Kemal Gungorduk; Jumana Muallem; Osman Aşıcıoğlu; Varol Gülseren; Ümran Küçükgöz Güleç; Mehmet Mutlu Meydanlı; Jalid Sehouli; Aykut Özdemir; Hanifi Şahin; Ghanim Khatib; Andrea Miranda; Nurettin Boran; Taylan Şenol; Nuri Yıldırım; Taner Turan; Tufan Oge; Salih Taşkın; Mehmet Ali Vardar; Ali Ayhan; Mustafa Zelal Muallem
Journal:  Arch Gynecol Obstet       Date:  2021-08-27       Impact factor: 2.344

2.  Magnetic resonance imaging pitfalls in determining myometrial invasion in stage I endometrial cancer: A case report and literature review.

Authors:  Hariyono Winarto; Muhammad Habiburrahman; Trifonia Pingkan Siregar; Kartiwa Hadi Nuryanto
Journal:  Radiol Case Rep       Date:  2022-05-29

Review 3.  Endometrial Cancer MRI staging: Updated Guidelines of the European Society of Urogenital Radiology.

Authors:  Stephanie Nougaret; Mariana Horta; Evis Sala; Yulia Lakhman; Isabelle Thomassin-Naggara; Aki Kido; Gabriele Masselli; Nishat Bharwani; Elizabeth Sadowski; Andrea Ertmer; Milagros Otero-Garcia; Rahel A Kubik-Huch; Teresa M Cunha; Andrea Rockall; Rosemarie Forstner
Journal:  Eur Radiol       Date:  2018-07-11       Impact factor: 5.315

4.  Myometrium Invasion, Tumour Size and Lymphovascular Invasion as a Prognostic Factor in Dissemination of Pelvic Lymphatics at Endometrial Carcinoma.

Authors:  Nenad Lucic; Dragica Draganovic; Sanja Sibincic; Vesna Ecim-Zlojutro; Snjezana Milicevic
Journal:  Med Arch       Date:  2017-10

5.  Is Tumor-Free Distance an Independent Prognostic Factor for Early-Stage Endometrioid Endometrial Cancer?

Authors:  Tufan Oge; Duygu Kavak Comert; Yusuf Cakmak; Deniz Arık
Journal:  J Oncol       Date:  2020-04-14       Impact factor: 4.375

6.  Can addition of frozen section analysis to preoperative endometrial biopsy and MRI improve identification of high-risk endometrial cancer patients?

Authors:  Go Nakai; Yoshikazu Tanaka; Takashi Yamada; Masahide Ohmichi; Kazuhiro Yamamoto; Keigo Osuga
Journal:  BMC Cancer       Date:  2021-11-04       Impact factor: 4.430

7.  Impact of lymphadenectomy on short- and long-term complications in patients with endometrial cancer.

Authors:  Lars C Hanker; Georgios Gitas; Louisa Proppe; Ibrahim Alkatout; Ricarda Koch; Sascha Baum; Christos Kotanidis; Achim Rody
Journal:  Arch Gynecol Obstet       Date:  2022-01-17       Impact factor: 2.493

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.